SeraCare, based in Milford, Mass., performs contract research services, and its portfolio includes diagnostic controls and molecular biomarkers. Linden Capital is a Chicago-based private equity firm that focuses on healthcare and life sciences.
Under terms of the deal announced Monday, Linden Capital will pay $4 for each SeraCare share, a 12 percent premium compared to the stock's closing price of $3.58 on Friday.
The company had about 19.4 million shares as of its latest earnings report.
SeraCare said the price represents a 25 percent premium to the 30-day volume-weighted average stock price.
Its board has unanimously recommended the deal to its shareholders who will get a chance to vote on it.
The companies expect the deal to close in the second quarter.
StreetBeat Disclaimer
No comments:
Post a Comment